EU/3/10/728: Orphan designation for the treatment of progressive supranuclear palsy

Davunetide

Table of contents

Overview

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor.

On 23 March 2010, orphan designation (EU/3/10/728) was granted by the European Commission to FGK Representative Service GmbH, Germany, for davunetide for the treatment of progressive supranuclear palsy.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Davunetide
Intended use
Treatment of progressive supranuclear palsy
Orphan designation status
Withdrawn
EU designation number
EU/3/10/728
Date of designation
23/03/2010
Sponsor

FGK Representative Service GmbH
Heimeranstrasse 35
80339 Munich
Germany
Bavaria
Tel. + 49 89 893 119 22
Fax + 49 89 893 119 20
E-mail: info@fgk-rs.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating